| This week's sponsor is Premier Research. | |  | Immunotherapy: Unleashing the Body's Potential to Fight Cancer
The immune system's role in fighting cancer becomes clearer every day, and the therapeutic implications are enormous. Discover promising new approaches to immunotherapy in our new white paper.
Premier Research. It's what we do. Best. |
Featured Story | | | Thursday, June 29, 2017 Doug Ingram has become the latest person to take a turn as Sarepta Therapeutics CEO. The former Allergan president is set to replace Ed Kaye, M.D., putting him in charge of turning Sarepta into a successful commercial-stage biotech with a pipeline of promising programs. |
|
|
| This week's sponsor is Sensors Expo & Conference 2017. | |  | |
Top Stories Thursday, June 29, 2017 The FDA's rejection of Coherus BioSciences' biosimilar version of Amgen's Neulasta means that 51 people at the company will lose their jobs, reducing its headcount by around 30%. Thursday, June 29, 2017 Merck KGaA has taken its oncology collaboration with Cancer Research Technology (CRT) to the next level. The move sees Merck and CRT kick off a full drug discovery program aimed at the Hippo pathway after spending a year on target validation. Monday, June 26, 2017 Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer. Thursday, June 29, 2017 Cambridge venture capital firm Atlas Venture has raised its 11th fund, totaling $350 million, as it looks to advance its mission of “doing well by doing good” for biotechs. Wednesday, June 28, 2017 Evotec has reached a collaboration with Censo Biotechnologies, using the latter’s patient-derived induced pluripotent stem cells to expand its platform for drug discovery. Thursday, June 29, 2017 After recently merging with fellow CRO InVentiv in a new company worth around $7.4 billion, INC says it is now focused on growing its Asia presence with moves and an expansion. Wednesday, June 28, 2017 Johnson & Johnson’s DePuy Synthes has acquired Sentio, which makes nerve localization technology for spine surgery, for an undisclosed amount. Wednesday, June 28, 2017 While Republican senators work feverishly on a healthcare bill, one prominent pharma CEO says overhauling the system won't take a few weeks of work. Think years, even decades—and he'd like Democrats to be at the table, too. | This week's sponsor is J.P. Morgan Private Bank. | |  | How Your Assets Are Structured Can Have Long-Term Implications On Your Wealth
As a founder or executive of a healthcare business, it's crucial your assets are titled properly. J.P. Morgan Private Bank knows how to protect your assets and preserve your wealth. Download this article on asset ownership to learn more. |
| | | The FDA comes good on its orphan label backlog just one week after new Commissioner Scott Gottlieb's promise to the Senate. FDA statement Omeros is biting back at a highly critical report, accusing “Art Doyle” of shorting the stock and calling the report "replete with falsehoods, misleading statements and incorrect analyses and conclusions." Release Chi-Med and partner AstraZeneca have started their global late-stage test of savolitinib in papillary renal cell carcinoma. Statement | |
|
Resources Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Presented by: Veeva Hear three innovative leaders explain how regulatory can “go digital” in their operations by leveraging the data-handling capabilities in their RIM systems. Sponsored by Envigo Performing a sophisticated surgery to create a myocardial infarction model. Join us on June 7th at 11:00 AM EDT. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
